TI‐RADS and Bethesda Classification System Correlate With Predicting Pediatric Papillary Thyroid Carcinoma
Otolaryngology–Head and Neck Surgery · 2025
DOI: 10.1002/ohn.1310 ↗Kurz gefasst
Fachartikel in der Zeitschrift Otolaryngology–Head and Neck Surgery, 2025. Verfasst von Shaunak N Amin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, University of Washington, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Carcinoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 13 Literaturangaben. Gefördert von: NIDCD NIH HHS.
Abstract (Originalsprache)
Objective
Our study objectives were to evaluate the relationship between Thyroid Imaging Reporting and Data System (TI‐RADS) and Bethesda classification and to compare both TI‐RADS and Bethesda classification for the diagnosis of papillary thyroid carcinoma (PTC) within the pediatric population. Study Design Retrospective case series.
Setting
Academic pediatric hospital.
Methods
A 13‐year retrospective review was performed of all pediatric patients undergoing thyroid fine needle aspiration (FNA) and ultrasound at our institution. Demographics, TI‐RADS scoring, FNA results, surgical history, and final pathology were collected. High‐risk ultrasonography and cytopathology were defined as TI‐RADS 3‐5 and Bethesda 5‐6, respectively. Spearman's rank correlation was determined for TI‐RADS and Bethesda classification. Relative risks of high‐risk TI‐RADS and Bethesda classification for predicting PTC were calculated.
Results
A total of 157 patients (21.7% male, median age at time of FNA 15 years, and range 2.7‐21 years) underwent ultrasound and FNA during the study. The Spearman's rank correlation coefficient for TI‐RADS compared with the Bethesda classification was 0.41 ( P < .001). The relative risk of high‐risk TI‐RADS scores to predict the presence of PTC was 7.99 (95% CI 1.16‐54.90). High‐risk Bethesda classification demonstrated a relative risk for predicting PTC of 6.62 (95% CI 4.22‐10.41).
Conclusion
In our cohort, there was a moderate correlation between TI‐RADS and Bethesda classifications. Patients with a TI‐RADS score ≥3 and Bethesda classification 3 or 4 are at intermediate risk for harboring PTC and should be counseled accordingly.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck Surgery, University of Washington, Seattle, Washington, USA.
- University of Washington School of Medicine, Seattle, Washington, USA.
- Division of Pediatric Otolaryngology-Head and Neck Surgery, Seattle Children's Hospital, Seattle, Washington, USA.
- Walter Reed National Military Medical Center, Division of Pediatric Otolaryngology-Head and Neck Surgery, Bethesda, Maryland, USA.
- Department of Biostatistics, Seattle Children's Research Institute, Seattle, Washington, USA.
- Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
ORCID-Profile: Shaunak N Amin
Förderung
- NIDCD NIH HHS
Zitieren
APA
Amin, S. N., Branson, M., Perkins, J. N., Wang, X., Huang, E. C., Ketterl, T. G., Khalatbari, H., Parikh, S. R., Manning, S. C., & Dahl, J. P. (2025). TI‐RADS and Bethesda Classification System Correlate With Predicting Pediatric Papillary Thyroid Carcinoma. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.1310
Vancouver
Amin SN, Branson M, Perkins JN, Wang X, Huang EC, Ketterl TG, et al. TI‐RADS and Bethesda Classification System Correlate With Predicting Pediatric Papillary Thyroid Carcinoma. Otolaryngology–Head and Neck Surgery. 2025. doi:10.1002/ohn.1310
BibTeX
@article{Amin2025,
author = {Amin, Shaunak N and Branson, Megan and Perkins, J Nathaniel and Wang, Xing and Huang, Eric C and Ketterl, Tyler G and Khalatbari, Hedieh and Parikh, Sanjay R and Manning, Scott C and Dahl, John P},
title = {TI‐RADS and Bethesda Classification System Correlate With Predicting Pediatric Papillary Thyroid Carcinoma},
journal = {Otolaryngology–Head and Neck Surgery},
year = {2025},
doi = {10.1002/ohn.1310}
}
EUVIMED